- Home
- SPPL vs BOLT Comparison
SPPL vs BOLT Comparison
Compare SPPL & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- BOLT
- Stock Information
- Founded
- SPPL 2016
- BOLT 2015
- Country
- SPPL Singapore
- BOLT United States
- Employees
- SPPL N/A
- BOLT N/A
- Industry
- SPPL
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- BOLT Health Care
- Exchange
- SPPL Nasdaq
- BOLT Nasdaq
- Market Cap
- SPPL 9.8M
- BOLT 9.4M
- IPO Year
- SPPL 2023
- BOLT 2021
- Fundamental
- Price
- SPPL $3.11
- BOLT $5.19
- Analyst Decision
- SPPL
- BOLT Buy
- Analyst Count
- SPPL 0
- BOLT 3
- Target Price
- SPPL N/A
- BOLT $47.50
- AVG Volume (30 Days)
- SPPL 17.5K
- BOLT 14.4K
- Earning Date
- SPPL 01-01-0001
- BOLT 08-14-2025
- Dividend Yield
- SPPL N/A
- BOLT N/A
- EPS Growth
- SPPL N/A
- BOLT N/A
- EPS
- SPPL N/A
- BOLT N/A
- Revenue
- SPPL $2,764,846.00
- BOLT $4,167,000.00
- Revenue This Year
- SPPL N/A
- BOLT N/A
- Revenue Next Year
- SPPL N/A
- BOLT N/A
- P/E Ratio
- SPPL N/A
- BOLT N/A
- Revenue Growth
- SPPL N/A
- BOLT N/A
- 52 Week Low
- SPPL $2.16
- BOLT $4.59
- 52 Week High
- SPPL $16.80
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- SPPL 50.26
- BOLT 46.64
- Support Level
- SPPL $2.97
- BOLT $4.81
- Resistance Level
- SPPL $3.20
- BOLT $5.28
- Average True Range (ATR)
- SPPL 0.18
- BOLT 0.26
- MACD
- SPPL -0.00
- BOLT 0.01
- Stochastic Oscillator
- SPPL 33.45
- BOLT 70.26
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.